Transcatheter Valve Replacement: Risk Levels and Contemporary Outcomes
- Manuel ReyesEmail Manuel Reyes
- Michael J. Reardon
Transcatheter aortic valve replacement (TAVR) has exploded into medical care for aortic stenosis, thus changing the treatment options for patients. TAVR is currently approved for extreme-risk, high-risk, and intermediate-risk patients with symptomatic severe aortic stenosis, and randomized trials for low-risk patients are underway. This article traces the trajectory of TAVR as a viable option for higher-risk patients and examines current outcomes.
- Published on 1 Jul 2017
- Peer Reviewed